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at day 15 correlated with serum CTX-II (r = 0.72, p = 0.0004), but 
not with C2C (p = 0.132). Synovial CTX II measured at termina- 
tion day was 251.9 4- 118.3 pg/ml (mean 4- SD) and 7.64 4- 1.65 
pg/ml in CIA and control groups, respectively. Finally, serum CTX- 
I did not shown any differences between groups until day 23. At 
Day 23, a 66% elevation in bone resorption was observed in the 
CIA animals compared to control group (p < 0.05). 
Conclusion: C-telopeptide, but not helical, fragments of type II 
collagen is dramatically elevated in serum and synovial fluid as 
early as two weeks after immunization with type II collagen in the 
rat CIA-model. This accelerated cartilage degradation occurs si- 
multaneously with disease onset as evaluated by paw inflamma- 
tion. These observations suggest, that proteases different from 
aggrecanase are expressed early in this model of RA. 
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Aim: Type II collagen is abundantly and specifically found in car- 
tilage and its degradation generates fragments such as HELIX-II 
and CTX-II. These fragments, which originate from the triple heli- 
cal and C-telopeptide regions respectively, can be quantified us- 
ing specific immunoassays (Syncart TM and Cartilaps~u). Urinary 
HELIX-II and CTX-II concentrations are elevated in conditions of 
cartilage degradation, although their respective levels differ in OA 
and RA patients suggesting distinct collagenolytic pathways. The 
enzymes capable of cleaving type II collagen to release these 
fragments are currently unknown. We investigated the ability of 
cathepsins (Cat) and matrix metalloproteases (MMP) to digest 
native articular cartilage and to release the CTX-II and HELIX-II 
biomarkers. 
Methods: Human hip articular cartilage (5 mg/mL) was digested 
with 1 I~M human Cat B, L, K, S and D (pH 5.5) and 1 I~M hu- 
man MMP-1, -3, -7, -9 and -13 (pH 7.5) for 24 h at 37°C. The 
digestion of cartilage to release soluble peptides was determined 
by hydroxyproline and HELIX-II and CTX-II were determined by 
specific ELISAs. 
Results: All cathepsins and MMPs solubilised between 10% and 
70% of the native cartilage over 24 h, although the release of 
CTX-II and HELIX-II differed dramatically between enzymes. Cat 
B was the sole cathepsin capable of releasing significant quanti- 
ties of CTX-II, whereas HELIX-II was only released efficiently by 
Cat L and S and to a lower extent by Cat K. CTX-II was released 
by all MMPs tested, although the efficiency differed for each en- 
zyme. HELIX-II was released only by MMP-7, and to a lower ex- 
tent by MMP-3. The addition of MMPs to collagen fragments re- 
leased by Cat K from cartilage in a primary digestion, only re- 
leased small quantities of CTX-II and no further HELIX-II. CTX-II 
produced by cartilage digestion with MMP-7 was not destroyed 
by subequent incubations with cathepsins whereas HELIX-II frag- 
ments were completely cleaved by subsequent incubation with 
Cat B. 
Conclusion: Cathepsins and MMPs can both digest native carti- 
lage in vitro, but only distinct subsets of these enzymes generate 
CTX-II and HELIX-II fragments. These findings may provide a bio- 
logical rationale for the recent observation that the relative urinary 
abundance of HELIX-II and CTX-II differs between RA and OA 
patients and support the concept that specific protease inhibitors 
could be used selectively against given arthritis diseases. 
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Aim of study: to quantitate and determine relative chain lengths 
of HA and CS fragments in serum and synovial fluid. 
Methods: After proteinase K digestion, serum (1 ml) and syn- 
ovial fluid (0.25 ml) samples were fractionated by gel filtration 
columns packed with allyl dextran/bisacrylamide (Sephacryl S- 
1000) or agarose (Superose 6). S-1000 has a fractionation range 
(Mr) of 5×105 to >108 and Superose 6 has a range up to 
106. Larger fragments were eluted first, followed by progressively 
smaller fragments. The columns had values of V0 ~ 6 ml and 
Vt ~ 25 ml. Fractions (1 ml) 7 through 24 were collected and 
analyzed (S-1000 fractions designated A7 - A24 and Superose 
6 fractions designated B7 - B24). For serum, only Superose 
6 fractions were analyzed. Fractions were digested with chon- 
droitinase ACII/ABC and the disaccharide digests were labeled 
with 2-aminoacridone for fluorophore-assisted carbohydrate lec- 
trophoresis (FACE). FACE gels were photographed and analyzed 
with Kodak 1 D software. 
Results: Fluorotagged HA and CS digestion products from 
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Fig 1 HA/0S/6S/4S content in $1000 fractions (A7 A24) and Superose 6
fractions (B7-B24) of synovial fluid and serum from 9 normal horses. A: Syn- 
ovial fluid HA content. B: Synovial fluid CS content. C: Serum HA/0S/6S/4S 
content. 
